Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Profit After Tax (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of Profit After Tax data on record, last reported at -$38.3 million in Q3 2025.

  • For Q3 2025, Profit After Tax fell 45.09% year-over-year to -$38.3 million; the TTM value through Sep 2025 reached $40.6 million, up 138.47%, while the annual FY2024 figure was -$89.0 million, 15.01% up from the prior year.
  • Profit After Tax reached -$38.3 million in Q3 2025 per STOK's latest filing, down from -$23.5 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $112.9 million in Q1 2025 and bottomed at -$38.3 million in Q3 2025.
  • Average Profit After Tax over 4 years is -$16.2 million, with a median of -$25.7 million recorded in 2022.
  • The widest YoY moves for Profit After Tax: up 527.99% in 2025, down 45.09% in 2025.
  • A 4-year view of Profit After Tax shows it stood at -$25.7 million in 2022, then fell by 5.08% to -$27.0 million in 2023, then soared by 61.12% to -$10.5 million in 2024, then plummeted by 265.85% to -$38.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Profit After Tax were -$38.3 million in Q3 2025, -$23.5 million in Q2 2025, and $112.9 million in Q1 2025.